JP4874102B2 - ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法 - Google Patents

９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法 Download PDF

Info

Publication number
JP4874102B2
JP4874102B2 JP2006528316A JP2006528316A JP4874102B2 JP 4874102 B2 JP4874102 B2 JP 4874102B2 JP 2006528316 A JP2006528316 A JP 2006528316A JP 2006528316 A JP2006528316 A JP 2006528316A JP 4874102 B2 JP4874102 B2 JP 4874102B2
Authority
JP
Japan
Prior art keywords
formula
reaction
scheme
mmol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006528316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506792A (ja
JP2007506792A5 (enExample
Inventor
ジェームズ ディー． マッチェスニー，
ジェームズ フェラーラ，
ジャン ジグムント，
Original Assignee
タペストリー ファーマシューティカルズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タペストリー ファーマシューティカルズ インコーポレーテッド filed Critical タペストリー ファーマシューティカルズ インコーポレーテッド
Publication of JP2007506792A publication Critical patent/JP2007506792A/ja
Publication of JP2007506792A5 publication Critical patent/JP2007506792A5/ja
Application granted granted Critical
Publication of JP4874102B2 publication Critical patent/JP4874102B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2006528316A 2003-09-25 2004-09-27 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法 Expired - Lifetime JP4874102B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50668003P 2003-09-25 2003-09-25
US60/506,680 2003-09-25
PCT/US2004/031816 WO2005030150A2 (en) 2003-09-25 2004-09-27 9,10-α,α-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010200399A Division JP5525394B2 (ja) 2003-09-25 2010-09-07 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
JP2011086840A Division JP5629632B2 (ja) 2003-09-25 2011-04-08 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法

Publications (3)

Publication Number Publication Date
JP2007506792A JP2007506792A (ja) 2007-03-22
JP2007506792A5 JP2007506792A5 (enExample) 2010-10-28
JP4874102B2 true JP4874102B2 (ja) 2012-02-15

Family

ID=34393186

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006528316A Expired - Lifetime JP4874102B2 (ja) 2003-09-25 2004-09-27 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
JP2010200399A Expired - Lifetime JP5525394B2 (ja) 2003-09-25 2010-09-07 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
JP2011086840A Expired - Lifetime JP5629632B2 (ja) 2003-09-25 2011-04-08 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
JP2014141964A Expired - Lifetime JP6106634B2 (ja) 2003-09-25 2014-07-10 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
JP2016137271A Expired - Lifetime JP6216417B2 (ja) 2003-09-25 2016-07-12 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010200399A Expired - Lifetime JP5525394B2 (ja) 2003-09-25 2010-09-07 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
JP2011086840A Expired - Lifetime JP5629632B2 (ja) 2003-09-25 2011-04-08 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
JP2014141964A Expired - Lifetime JP6106634B2 (ja) 2003-09-25 2014-07-10 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
JP2016137271A Expired - Lifetime JP6216417B2 (ja) 2003-09-25 2016-07-12 ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法

Country Status (14)

Country Link
US (8) US7745650B2 (enExample)
EP (2) EP1664033B1 (enExample)
JP (5) JP4874102B2 (enExample)
CN (1) CN1886400A (enExample)
AT (1) ATE377593T1 (enExample)
AU (1) AU2004275881A1 (enExample)
CA (1) CA2539975C (enExample)
DE (1) DE602004009943T2 (enExample)
DK (1) DK1664033T3 (enExample)
ES (1) ES2295937T3 (enExample)
HR (1) HRP20080057T3 (enExample)
PL (1) PL1664033T3 (enExample)
PT (1) PT1664033E (enExample)
WO (1) WO2005030150A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1664033B1 (en) 2003-09-25 2007-11-07 Tapestry Pharmaceuticals, Inc. 9,10-alpha,alpha-oh-taxane analogs and methods for production the reof
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
WO2007073383A1 (en) * 2005-12-21 2007-06-28 Tapestry Pharmaceuticals, Inc. Novel compounds and methods for forming taxanes and using the same
JP2009521463A (ja) * 2005-12-21 2009-06-04 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体のための方法およびそれに有用な中間体
JP2009531446A (ja) * 2006-03-27 2009-09-03 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体の合成のためのコンバージェントプロセス
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US7847111B2 (en) 2006-06-19 2010-12-07 Canada Inc. Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III
EP2029563A4 (en) * 2006-06-12 2009-12-02 Canada Inc 6570763 HALF-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US9227983B2 (en) 2011-04-07 2016-01-05 Arbor Therapeutics, LLC Taxane and abeo-taxane analogs
KR20140048113A (ko) * 2011-04-07 2014-04-23 아버 테라퓨틱스 엘엘씨 탁산 및 아베오-탁산 유사체
AU2012275953B2 (en) * 2011-06-06 2015-01-22 Arbor Therapeutics, LLC Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents
DK4096588T3 (da) 2020-03-04 2024-10-21 Aquedeon Medical Inc Instrument til anlæggelse af en vaskulær og aortatransplantat konnektor med teleskopskede

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US6794523B2 (en) * 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
DK0639186T3 (da) * 1992-04-17 1999-12-13 Abbott Lab Taxolderivater
FR2697019B1 (fr) * 1992-10-15 1994-11-25 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
JPH08503218A (ja) * 1992-11-13 1996-04-09 フロリダ・ステート・ユニバーシティー ブテニル置換タキサンおよび組成物
US6066747A (en) * 1993-03-05 2000-05-23 Florida State University Process for the preparation of 9-desoxotaxanes
US6710191B2 (en) * 1993-03-05 2004-03-23 Florida State University 9β-hydroxytetracyclic taxanes
DE69430797T2 (de) 1993-03-05 2003-02-27 Florida State University, Tallahassee C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
ATE295164T1 (de) * 1993-03-22 2005-05-15 Univ Florida State Taxane mit furyl oder thienyl enthaltender substituierter seitenkette
FR2707293A1 (fr) 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2715846A1 (fr) * 1994-02-07 1995-08-11 Rhone Poulenc Rorer Sa Nouvelle composition pharmceutique à base de taxoïdes.
IT1275936B1 (it) 1995-03-17 1997-10-24 Indena Spa Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
US5635531A (en) * 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
US5739359A (en) 1997-01-24 1998-04-14 Virginia Tech Intellectual Properties, Inc. Methods for preparing 1-deoxy paclitaxels
US6048990A (en) * 1998-05-01 2000-04-11 Napro Biotherapeutics, Inc. Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position
CO5280224A1 (es) * 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
HK1047896A1 (zh) 2000-02-02 2003-03-14 佛罗里达州立大学研究基金有限公司 C10杂取代的乙酸基紫衫烷抗肿瘤剂
JP2004528309A (ja) 2001-03-23 2004-09-16 ナプロ バイオセラピューティクス，インコーポレイテッド 癌治療用分子複合体
CA2354471A1 (en) 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
AU2002361701A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Pharmaceutical compositons of orally active taxane derivatives having enhanced bioavailability
US6898834B1 (en) * 2003-03-03 2005-05-31 Westbridge Pty Ltd Barrel stave reclaim
EP1894921A3 (en) 2003-09-25 2008-03-12 Tapestry Pharmaceuticals, Inc. 9, 10-Alpha, Alpha-Oh-Taxane analogs and methods for production thereof
EP1664033B1 (en) * 2003-09-25 2007-11-07 Tapestry Pharmaceuticals, Inc. 9,10-alpha,alpha-oh-taxane analogs and methods for production the reof
AU2006247471A1 (en) 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
WO2007073383A1 (en) 2005-12-21 2007-06-28 Tapestry Pharmaceuticals, Inc. Novel compounds and methods for forming taxanes and using the same
JP2009521463A (ja) 2005-12-21 2009-06-04 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体のための方法およびそれに有用な中間体
JP2009531446A (ja) 2006-03-27 2009-09-03 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体の合成のためのコンバージェントプロセス
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
US20080207743A1 (en) 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment

Also Published As

Publication number Publication date
US8962870B2 (en) 2015-02-24
US20160331718A1 (en) 2016-11-17
US20180125811A1 (en) 2018-05-10
JP2007506792A (ja) 2007-03-22
JP2011012070A (ja) 2011-01-20
US20100324128A1 (en) 2010-12-23
JP6216417B2 (ja) 2017-10-18
EP1664033A2 (en) 2006-06-07
US20120077871A1 (en) 2012-03-29
ES2295937T3 (es) 2008-04-16
EP1785416A2 (en) 2007-05-16
PL1664033T3 (pl) 2008-04-30
JP2014196345A (ja) 2014-10-16
JP6106634B2 (ja) 2017-04-05
US20150133536A1 (en) 2015-05-14
US20190142784A1 (en) 2019-05-16
US20200237708A1 (en) 2020-07-30
JP5629632B2 (ja) 2014-11-26
US9820962B2 (en) 2017-11-21
AU2004275881A1 (en) 2005-04-07
JP2011137045A (ja) 2011-07-14
US10639293B2 (en) 2020-05-05
ATE377593T1 (de) 2007-11-15
CA2539975C (en) 2012-11-20
EP1785416A3 (en) 2007-05-30
JP2016180006A (ja) 2016-10-13
EP1664033A4 (en) 2006-09-13
JP5525394B2 (ja) 2014-06-18
CA2539975A1 (en) 2005-04-07
DK1664033T3 (da) 2008-03-25
DE602004009943T2 (de) 2008-08-28
US10238621B2 (en) 2019-03-26
US9402824B2 (en) 2016-08-02
EP1664033B1 (en) 2007-11-07
CN1886400A (zh) 2006-12-27
US7879904B2 (en) 2011-02-01
WO2005030150A2 (en) 2005-04-07
HRP20080057T3 (en) 2008-02-29
WO2005030150A3 (en) 2005-07-14
DE602004009943D1 (de) 2007-12-20
US7745650B2 (en) 2010-06-29
US20050148657A1 (en) 2005-07-07
PT1664033E (pt) 2008-01-17

Similar Documents

Publication Publication Date Title
JP6216417B2 (ja) ９，１０−α，α−ＯＨ−タキサンアナログおよびその生成のための方法
EP0773938B1 (en) Semi-synthetic taxanes with anti-tumoural activity
US20110028539A1 (en) Biologically active taxane analogs and methods of treatment
JP2002505326A (ja) 強塩基と求電子を用いる、７−ヒドロキシルの保護によるバッカチンｉｉｉからのパクリタキセルの合成
KR19980702749A (ko) 10-데아세틸-14베타-하이드록시바카틴iii 유도체, 그의 제조방법 및 그를 함유한 제제.
EP1894921A2 (en) 9, 10-Alpha, Alpha-Oh-Taxane analogs and methods for production thereof
HK1011687B (en) Semi-synthetic taxanes with anti-tumoural activity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100907

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100907

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111122

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4874102

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term